A 35-year-old male with schizophrenia, treated with olanzapine for 2 years, presents for a routine check-up. His BMI has increased from 24 to 31, and recent lab tests show elevated fasting glucose and dyslipidemia. Which of the following antipsychotics is most likely to cause a similar metabolic side effect profile?

Explanation

Olanzapine is well-known for its high propensity to cause weight gain, dyslipidemia, and hyperglycemia, collectively known as metabolic syndrome. Among the given options, Clozapine shares a similar high risk for metabolic side effects, often considered to have the highest risk alongside olanzapine. Haloperidol (a typical antipsychotic) has a lower metabolic risk. Risperidone has an intermediate metabolic risk. Ziprasidone is known for its relatively low metabolic risk.